Egaptivon pegol
Explore a selection of our essential drug information below, or:
Overview
- DrugBank ID
- DB05202
- Type
- Biotech
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 1
- Phase 2
- 13
- Phase 3
- 0
- Phase 4
- 0
Identification
- Generic Name
- Egaptivon pegol
- DrugBank Accession Number
- DB05202
- Background
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.1,2 Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.1
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Egaptivon pegol
- External IDs
- ARC 1779
- ARC-1779
- ARC1779
Pharmacology
- Indication
Platelet aggregation, thrombosis and acute coronary syndromes
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart.
Target Actions Organism Uvon Willebrand factor Not Available Humans UPlatelet glycoprotein Ib alpha chain Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
ARC1779 was shown to bind specifically to activated vWF. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots.
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAntihemophilic factor (recombinant), PEGylated The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Egaptivon pegol. Certolizumab pegol The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Egaptivon pegol. Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Egaptivon pegol. Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Egaptivon pegol. Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Egaptivon pegol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DT0445S65M
- CAS number
- 934868-74-3
References
- General References
- Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG: First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007 Dec 4;116(23):2678-86. Epub 2007 Nov 19. [Article]
- Veyradier A: A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis. Haematologica. 2020 Nov 1;105(11):2512-2515. doi: 10.3324/haematol.2020.261081. [Article]
- External Links
- PubChem Substance
- 347910022
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Thrombotic Thrombocytopenic Purpura (TTP) / Von Willebrand Disease, Type 2B 1 somestatus stop reason just information to hide 2 Terminated Treatment Cerebral Embolism and Thrombosis / Intracranial Embolism / Stenosis, Carotid 1 somestatus stop reason just information to hide 2 Terminated Treatment Thrombotic Microangiopathies / Thrombotic Thrombocytopenic Purpura (TTP) 1 somestatus stop reason just information to hide 2 Withdrawn Treatment Von Willebrand's Disease 1 somestatus stop reason just information to hide 1 Completed Treatment Thrombosis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma
- Specific Function
- collagen binding
- Gene Name
- VWF
- Uniprot ID
- P04275
- Uniprot Name
- von Willebrand factor
- Molecular Weight
- 309261.83 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium
- Specific Function
- thrombin-activated receptor activity
- Gene Name
- GP1BA
- Uniprot ID
- P07359
- Uniprot Name
- Platelet glycoprotein Ib alpha chain
- Molecular Weight
- 71539.265 Da
Drug created at October 21, 2007 22:24 / Updated at July 18, 2023 22:56